3/19
04:55 pm
sabs
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
Low
Report
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
3/19
04:01 pm
sabs
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
Low
Report
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
3/17
10:46 pm
sabs
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
Medium
Report
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
3/17
04:43 pm
sabs
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
Medium
Report
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
3/17
04:15 pm
sabs
SAB Biotherapeutics announces public stock offering; shares down [Seeking Alpha]
Medium
Report
SAB Biotherapeutics announces public stock offering; shares down [Seeking Alpha]
3/17
04:01 pm
sabs
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Medium
Report
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
3/14
06:59 am
sabs
SAB Biotherapeutics (SABS) was downgraded by Zacks Research from "hold" to "strong sell".
Medium
Report
SAB Biotherapeutics (SABS) was downgraded by Zacks Research from "hold" to "strong sell".
3/14
01:32 am
sabs
Medium
Report
3/11
03:02 pm
sabs
SAB Biotherapeutics (SABS) had its price target raised by Chardan Capital from $12.00 to $14.00. They now have a "buy" rating on the stock.
Low
Report
SAB Biotherapeutics (SABS) had its price target raised by Chardan Capital from $12.00 to $14.00. They now have a "buy" rating on the stock.
3/10
08:03 am
sabs
SAB Biotherapeutics (SABS) had its price target lowered by HC Wainwright from $9.00 to $7.00. They now have a "buy" rating on the stock.
Medium
Report
SAB Biotherapeutics (SABS) had its price target lowered by HC Wainwright from $9.00 to $7.00. They now have a "buy" rating on the stock.
3/10
07:42 am
sabs
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes [Yahoo! Finance]
Medium
Report
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes [Yahoo! Finance]
3/10
07:31 am
sabs
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
Medium
Report
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
3/9
05:59 pm
sabs
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights [Yahoo! Finance]
Medium
Report
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights [Yahoo! Finance]
3/9
05:16 pm
sabs
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
Medium
Report
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
3/2
09:00 am
sabs
SAB BIO to Participate in Upcoming Investor Conferences
Medium
Report
SAB BIO to Participate in Upcoming Investor Conferences
3/2
12:12 am
sabs
SAB Biotherapeutics Pitches SAB-142 as Redosable Human ATG for Type 1 Diabetes at Oppenheimer Conf [Yahoo! Finance]
Low
Report
SAB Biotherapeutics Pitches SAB-142 as Redosable Human ATG for Type 1 Diabetes at Oppenheimer Conf [Yahoo! Finance]
2/4
09:00 am
sabs
SAB BIO to Participate in Upcoming Investor Conferences
Medium
Report
SAB BIO to Participate in Upcoming Investor Conferences
1/9
06:10 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Low
Report
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
1/7
08:00 am
sabs
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
Medium
Report
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
1/7
02:01 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
Medium
Report
SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
1/6
08:00 am
sabs
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/23
07:06 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
Low
Report
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at Guggenheim to a "strong-buy" rating.